Intellia Therapeutics
NTLA
319 hedge funds and large institutions have $3.81B invested in Intellia Therapeutics in 2022 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 114 increasing their positions, 96 reducing their positions, and 26 closing their positions.
85% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 26
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
27% more call options, than puts
Call options by funds: $48.5M | Put options by funds: $38.2M
19% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 96
11% more capital invested
Capital invested by funds: $3.42B → $3.81B (+$385M)
7% more funds holding
Funds holding: 299 → 319 (+20)
0.41% more ownership
Funds ownership: 89.13% → 89.54% (+0.41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$19.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$18.6M |
| 3 |
CC
Casdin Capital
New York
|
+$18.3M |
| 4 |
Morgan Stanley
New York
|
+$18.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$28.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$28.3M |
| 4 |
D.E. Shaw & Co
New York
|
-$23.2M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$21M |
NTLA Hedge Fund Activity: Q3 2022 in Review
319 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2022, worth a combined $3.81B — up 11% from $3.42B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new NTLA positions and 26 closed out — a net gain of 22 holders — while 114 added to existing stakes and 96 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $19.8M. The largest seller was Fidelity Investments, cutting an estimated $42.1M.
- 319 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2022, up from 299 in Q2 2022.
- Funds reported $3.81B of Intellia Therapeutics stock for Q3 2022, up 11% quarter-over-quarter.
- 48 funds opened new Intellia Therapeutics positions in Q3 2022 and 26 closed out, a net change of +22 holders.
- The largest Intellia Therapeutics buyer in Q3 2022 was Eventide Asset Management, an estimated $19.8M added.
- The largest Intellia Therapeutics seller in Q3 2022 was Fidelity Investments, an estimated $42.1M sold.
Based on aggregated 13F filings for Q3 2022.